CAR T-Cell Therapy Outperformed Bispecifics in Lymphoma Study
Patients with relapsed mantle cell lymphoma saw higher response rates, though safety profiles remain a critical consideration.
Updated on Oct. 13, 2026 in Cancer
A 2024 meta-analysis revealed that CAR T-cell therapy resulted in higher complete response rates compared to bispecific antibodies for patients with relapsed mantle cell lymphoma. This synthesis of clinical data provides new insight for older adults navigating difficult treatment decisions.
Why it matters
In the absence of head-to-head randomized trials, this analysis helps fill a critical gap in understanding how these complex immunotherapies compare for patients who have already undergone multiple lines of treatment. It highlights the importance of weighing efficacy against the potential for significant side effects.
This meta-analysis pooled data from 237 patients, with a median age range of 65 to 68.5 years, who received treatments including mosunetuzumab, glofitamab, brexucabtagene autoleucel, or lisocabtagene maraleucel. Findings are considered preliminary until confirmed by future randomized trials.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products including cellular immunotherapies.
The details
CAR T-cell therapy involves engineering a patient's own T-cells to identify and destroy lymphoma cells, whereas bispecific antibodies act as a bridge to pull immune cells toward cancer cells. While the meta-analysis showed superior response rates for CAR T-cell treatments, it also identified a 21% incidence of grade 3 or higher neurotoxicity in that group. Researchers utilized random-effects models to compare these distinct immunotherapy approaches for patients with at least two prior lines of therapy.
Timeline
October 2024: The literature search for the meta-analysis was completed.
April 3, 2026: The FDA granted traditional approval to brexucabtagene autoleucel.
Health Landscape
This analysis builds upon the current regulatory landscape for CAR T-cell therapies, such as brexucabtagene autoleucel. It serves to better contextualize how these newer, targeted immunotherapy options perform in the absence of direct, large-scale randomized trials.
If you are managing relapsed mantle cell lymphoma, these results underscore the importance of discussing the trade-offs between immunotherapy efficacy and side effect profiles like neurotoxicity with your oncology team. Tracking how these systemic treatments impact your quality of life is a vital part of your care conversation.
The takeaway
While CAR T-cell therapy shows higher response rates for this patient population, the risk of severe neurotoxicity remains a significant factor to monitor. Keep a detailed log of any neurological changes to share with your physician during clinical consultations.
Further reading
For more on evolving treatment options, visit the Cancer section.
